Research Papers:

CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma

Zhenxian Hu and Chenliang He _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:21167-21176. https://doi.org/10.18632/oncotarget.15504

Metrics: PDF 1371 views  |   HTML 1761 views  |   ?  


Zhenxian Hu1, Chenliang He1

1Department of Ophthalmology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China

Correspondence to:

Chenliang He, email: [email protected]

Keywords: CDKN2B, single nucleotide polymorphism, glaucoma, meta-analysis, rs1063192

Received: December 20, 2016     Accepted: February 08, 2017     Published: February 18, 2017


The aim of this meta-analysis was to evaluate the association between cyclin-dependent kinase Inhibitor-2B (CDKN2B) gene rs1063192 polymorphism and glaucoma risk. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 14 case-control studies involving 11,316 cases and 24,055 controls were included. Meta-analysis showed that CDKN2B gene rs1063192 polymorphism was associated with a decreased risk of glaucoma. Stratification analysis of ethnicity indicated that rs1063192 polymorphism decreased the risk of glaucoma among Caucasians and Asians. Stratification analysis by type of glaucoma revealed that rs1063192 polymorphism conferred a protective factor of primary open-angle glaucoma (POAG) and non-POAG. Stratification by source of controls uncovered an association between rs1063192 polymorphism and glaucoma in groups of population-based controls. In conclusion, this meta-analysis indicates that CDKN2B gene rs1063192 polymorphism is significantly associated with a decreased risk of glaucoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15504